StockNews.AI
APYX
StockNews.AI
117 days

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

1. Apyx Medical will release Q1 fiscal results on May 8, 2025. 2. Management will host a conference call to discuss results. 3. Renuvion and J-Plasma technologies are backed by over 90 clinical papers. 4. The company focuses on innovative energy technology for medical applications.

Earnings
-2.43%Current Return
VS
+2.66%S&P 500
$0.899904/24 08:51 AM EDTEvent Start
$0.87804/25 03:14 PM EDTLatest Updated
4m saved
Insight
Article

FAQ

Why Neutral?

The upcoming earnings report's impact is uncertain, often leading to volatility. Previous earnings reports have had mixed impacts on stock prices in similar companies.

How important is it?

The scheduled earnings release directly impacts investor expectations and stock performance. Market reactions to such announcements can verify or challenge growth narratives.

Why Short Term?

The earnings report and conference call will affect stock price sentiment shortly. Historical trends indicate market reactions occur around earnings announcements.

Related Companies

MDMDSEERSPPI
April 24, 2025 08:45 ET  | Source: Apyx Medical Corporation CLEARWATER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2025 will be released before markets open on Thursday, May 8th. Management will host a conference call at 8:00 a.m. Eastern Time on Thursday, May 8th to discuss the results of the quarter, and to host a question-and-answer session. To listen to the call by phone, interested parties may dial 800-717-1738 (or 646-307-1865 for international callers) and provide access code 63341. Participants should ask for the “Apyx Medical Corporation Call”. A live webcast of the call will be accessible via the following link: Apyx Medical Earnings Webcast and via the Investor Relations section of the Company’s website, where it will be archived for future reference. Investor Relations Contact:Jeremy Feffer Managing Director LifeSci AdvisorsOP: 212-915-2568jfeffer@lifesciadvisors.com About Apyx Medical Corporation:Apyx Medical Corporation is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Platform Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion and J-Plasma offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The effectiveness of Renuvion and J-Plasma are supported by more than 90 clinical publications. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. For further information about the Company and its products, please refer to the Apyx Medical Corporation website at www.ApyxMedical.com

Related News